Ixazomib Rollover Study

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 16, 2016

Primary Completion Date

July 3, 2024

Study Completion Date

July 3, 2024

Conditions
Multiple MyelomaLymphomaAmyloidosis
Interventions
DRUG

Ixazomib

Ixazomib Capsules

Trial Locations (26)

3000

UZ Leuven, Leuven

5505

Asan Medical Center - PPDS, Seoul

11528

University of Athens Medical School - Regional General Hospital Alexandra, Athens

20014

Hospital Universitario de Donostia, Donostia / San Sebastian

22185

Skanes Universitetssjukhus Lund, Lund

30322

Emory University, Atlanta

37007

Complejo Asistencial Universitario de Salamanca H. Clinico, Salamanca

41701

Appalachian Regional Healthcare, Hazard

63110

Washington University School of Medicine, St Louis

100191

Peking University Third Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

119082

National University Hospital, Singapore

200003

Shanghai Chang Zheng Hospital, Shanghai

310003

1st Affiliated Hospital of Zhejiang University, Hangzhou

02215

Dana Farber Cancer Institute, Boston

M5G 1X5

Princess Margaret Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

115 27

Laiko General Hospital of Athens, Athens

113-8677

Tokyo Metropolitan Komagome Hospital, Bunkyo-Ku

150-8935

Japanese Red Cross Medical Center, Shibuya-Ku

41-500

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzów

93-510

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz

20-090

Centrum Onkologii Ziemi Lubelskiej, Lublin

02-106

MTZ Clinical Research Sp z o o, Warsaw

Unknown

Karolinska Universitetssjukhuset Huddinge, Stockholm

SE-17176

Karolinska Universitetssjukhuset Solna, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Takeda

INDUSTRY